Page 5 - Spirovant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article ResearchAndMarkets.com's offering. "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global CFTR Modulators market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 4 commercially available CFTR Modulators with their, market share and the clinical profile. The advent of CFTR modulators in the management ...

Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA (vibegron), in the Journal of Urology Urovant Sciences, a wholly owned subsidiary of Sumitovant, announced today that the Journal of Urology has published positive safety and efficacy data from the GEMTESA (vibegron) double-blind 40-week extension study with patient data over a total exposure of 52 weeks (NCT03583372) in the print version of the Journal of Urology. The peer-reviewed publication is currently available online and the print arti...

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids •LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline •Achieved six of seven key secondary endpoints including reduction of pain •Bone mineral density maintained at levels comparable to placebo •Data were included in U.S. New Drug Application for relugolix combination tablet for ut...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant ... Sumitovant BiopharmaFebruary 18, 2021 GMT New York, London, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of Medicine published Myovant Sciences’ Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and...

Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results SEC reviewing preliminary proxy statement for the previously announced merger of the Company with Sumitovant Biopharma Special General Meeting of Shareholders to approve the merger is expected to occur by the end of 1Q CY2021 U.S. commercial launch of GEMTESA (vibegron) to treat OAB is on track for late-Q1 CY2021, following U.S. FDA approval in December 2020 Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended December 31, 2020. "The third quarter of fiscal 2020 ...